Most patients with breast cancer are detected after symptoms occur rather than through screening.
The impact on survival of delays between the onset of symptoms and the start of treatment is controversial and cannot be studied in randomised controlled trials.
We did a systematic review of observational studies (worldwide) of duration of symptoms and survival. (...) Interpretation : Delays of 3-6 months are associated with lower survival.
These effects cannot be accounted for by lead-time bias.
Efforts should be made to keep delays by patients and providers to a minimum.
Mots-clés Pascal : Tumeur maligne, Glande mammaire, Enquête, Survie
Mots-clés Pascal anglais : Malignant tumor, Mammary gland, Survey, Survival
Notice produite par :
ENSP - Ecole nationale de la santé publique (devenue EHESP)
Cote : 99/04 V
Code Inist : 002B30A11. Création : 16/11/1999.